1. Generics Bulletin
  2. >>Business

Gloomy First Half Results For Mayne

While Restructuring Gains Pace With $90m Generics Selloff

 
• By Rosalind Rei

Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market

Acronym for Australian dollar (AUD) on a digital screen next to downward red arrow icon
• Source: Shutterstock

Mayne’s financial situation continued to suffer from retail generics competition over the first half of its 2023 financial year ending June 2023.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.

How To Make The Most Of Your GGB Awards Entries

 
• By Dave Wallace

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

Denosumab Race Heats Up In Europe With Eight More Nods

 
• By Dave Wallace

Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.